<DOC>
	<DOCNO>NCT02719028</DOCNO>
	<brief_summary>Identified efficacy Antroquinonol ( Hocena 50mg ) triglyceride , lipid-lowering fatty liver .</brief_summary>
	<brief_title>Trial Antroquinonol Patients With Hypercholesterolemia Hyperlipidemia</brief_title>
	<detailed_description>The primary efficacy objective demonstrate reduction triglyceride ( TG ) Antroquinonol , comparison placebo , 12 week treatment patient hypercholesterolemia hyperlipidemia . Secondary objective include evaluation effect Antroquinonol comparison placebo lipid parameter 12 week treatment effect Antroquinonol leave ventricular diastolic function , arterial stiffness fatty liver . The safety tolerability Antroquinonol monitor well .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Ubiquinone</mesh_term>
	<criteria>1 . Adults either sex 30 75 year age , inclusive , diagnosis nonfamilial hypercholesterolemia mixed hyperlipidemia one following : TG 150 mg/dL 500 mg/dL , cholesterol 160 mg/dL 250 mg/dL TG 150 mg/dL 500 mg/dL LDLC &gt; 130 mg/dL ) ; 2 . Subject must free clinically significant disease , nonfamilial hypercholesterolemia mixed hyperlipidemia would knowingly interfere study evaluation ; 3 . A washout period 2 week apply patient prior treat lipidlowering medication ; 4 . Subject must willing adhere protocol requirement , provide write informed consent ; 5 . Female childbearing potential must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation . 1 . Patients secondary dyslipidemia cause diabetes mellitus , hypothyroidism , obstructive liver disease , chronic renal failure drug increase LDLC level ( e.g . retinoids , cyclosporine A phenothiazine ) decrease HDLC level ( e.g . progestin , androgen , Î²blockers , probucol anabolic steroid ) 2 . Patients lifestyle may interfere treatment efficacy , alcoholism drink habit 3 time per week , late dinner , late night supper , frequent oversea business traveler , frequent social gathering , patient anticipate diet control lifestyle change ; 3 . Patients diabetes history coronary artery disease ( myocardial infarction , cardiac intervention , cerebrovascular accident/stroke transient ischemic attack le 6 month prior Visit 1 ) ; 4 . Patients hypertension uncontrolled define 2 consecutive measurement sit blood pressure systolic &gt; 140 mmHg diastolic &gt; 90 mmHg Visit 1 ; 5 . Patient known hypersensitivity Antroquinonol related compound ; 6 . Patient uncontrolled intercurrent illness include , limited , acute decompensated HF ( exacerbation chronic HF manifest sign symptom may require IV therapy ) , right heart failure due severe pulmonary disease , diagnose peripartum chemotherapy induce cardiomyopathy within 12 month prior visit 1 , psychiatric illness/social situation would limit compliance study requirement ; 7 . Patients history heart transplant transplant list leave ventricular assistance device ( LVAD device ) ; 8 . Patients document ventricular arrhythmia syncopal episode within past 3 month prior visit 1 remain untreated ; 9 . Patients confirm severe primary pulmonary , renal ( eGFR &lt; 30 ml/min/1.73 m2 ) hepatic ( ChildPugh B/C classification ) disease ; 10 . Patients ca n't stop current lipid lower drug treatment base investigator 's judgement ; 11 . Patients malignancy , treat untreated , within past 5 year Visit 1 whether evidence local recurrence metastasis , exception localize basal cell carcinoma skin carcinoma situ cervix ; 12 . Female patient pregnancy , lactation breastfeeding ; 13 . Patient lifethreatening complication ; 14 . Patient consider unreliable medication compliance adherence schedule appointment , inappropriate inclusion determine investigator ; 15 . Any reason address investigator .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>